Suppr超能文献

帕金森病性精神病:更新。

Parkinson disease psychosis: Update.

机构信息

Movement Disorders Program, Butler Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA. Tel.: +1 401 455 6669; Fax: +1 401 455 6670; E-mail:

出版信息

Behav Neurol. 2013 Jan 1;27(4):469-77. doi: 10.3233/BEN-129016.

Abstract

Psychotic symptoms are common in drug treated patients with Parkinson's disease (PD). Visual hallucinations occur in about 30% and delusions, typically paranoid in nature, occur in about 5%. These problems, particularly the delusions, cause great distress for patient and caregivers, and are among the most important precipitants for nursing home placement. Psychotic symptoms carry a poor prognosis. They often herald dementia, and are associated with increased mortality. These symptoms often abate with medication reductions, but this may not be tolerated due to worsened motor function. Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not. While quetiapine has been recommended by the American Academy of Neurology for "consideration," double blind placebo controlled trials have demonstrated safety but not efficacy. Other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited. PDP remains a serious problem with limited treatment options.

摘要

精神病症状在帕金森病(PD)的药物治疗患者中很常见。约有 30%的患者出现幻觉,约 5%的患者出现妄想,通常是偏执性质的。这些问题,特别是妄想,给患者和护理人员带来了极大的痛苦,是导致入住养老院的最重要的诱因之一。精神病症状预后不良。它们常常预示着痴呆,并与死亡率增加有关。这些症状通常随着药物剂量的减少而减轻,但由于运动功能恶化,可能无法耐受。只有氯氮平具有 A 级证据支持其在伴有精神病(PDP)的 PD 患者中的使用,无论是否痴呆。虽然美国神经病学学会推荐使用喹硫平,但双盲安慰剂对照试验仅证明了其安全性,而没有证明其疗效。其他抗精神病药物已被报道会恶化运动功能,而关于胆碱酯酶抑制剂有效性的数据有限。PDP 仍然是一个严重的问题,治疗选择有限。

相似文献

1
Parkinson disease psychosis: Update.
Behav Neurol. 2013 Jan 1;27(4):469-77. doi: 10.3233/BEN-129016.
2
Treatment of psychosis in Parkinson's disease: safety considerations.
Drug Saf. 2003;26(9):643-59. doi: 10.2165/00002018-200326090-00004.
3
Parkinson's disease psychosis 2010: a review article.
Parkinsonism Relat Disord. 2010 Nov;16(9):553-60. doi: 10.1016/j.parkreldis.2010.05.004. Epub 2010 Jun 9.
4
Current Understanding of Psychosis in Parkinson's Disease.
Curr Psychiatry Rep. 2016 Oct;18(10):97. doi: 10.1007/s11920-016-0730-1.
5
Pharmacological interventions for psychosis in Parkinson's disease patients.
Expert Opin Pharmacother. 2018 Apr;19(5):499-505. doi: 10.1080/14656566.2018.1445721. Epub 2018 Mar 1.
6
Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
Clin Neuropharmacol. 2006 Nov-Dec;29(6):331-7. doi: 10.1097/01.WNF.0000236769.31279.19.
7
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Neuropsychopharmacology. 2010 Mar;35(4):881-92. doi: 10.1038/npp.2009.176. Epub 2009 Nov 11.
8
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
Drugs Aging. 2008;25(8):665-82. doi: 10.2165/00002512-200825080-00004.
9
Atypical antipsychotic drugs in the treatment of Parkinson's disease.
J Pharm Pract. 2011 Dec;24(6):534-40. doi: 10.1177/0897190011426556. Epub 2011 Nov 17.
10
Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Expert Opin Drug Saf. 2022 Jul;21(7):873-879. doi: 10.1080/14740338.2022.2069240. Epub 2022 May 3.

引用本文的文献

1
Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.
Ther Clin Risk Manag. 2022 Dec 20;18:1129-1142. doi: 10.2147/TCRM.S360268. eCollection 2022.
3
QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
Neuropsychiatr Dis Treat. 2021 Dec 24;17:3791-3818. doi: 10.2147/NDT.S324145. eCollection 2021.
5
Risk of Pneumonia is associated with Antipsychotic Drug Use among older patients with Parkinson's Disease: A Case-control Study.
Int J Med Sci. 2021 Aug 26;18(15):3565-3573. doi: 10.7150/ijms.63246. eCollection 2021.
6
Novel case of Parkinson's disease and schizophrenia: challenges in the management.
BMJ Case Rep. 2021 Jul 29;14(7):e244028. doi: 10.1136/bcr-2021-244028.
8
G-CSF mediated neutrophil augmentation in a unique case of comorbid idiopathic Parkinson's disease and treatment-resistant schizophrenia on clozapine.
Ther Adv Psychopharmacol. 2020 Sep 16;10:2045125320956414. doi: 10.1177/2045125320956414. eCollection 2020.
9
Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.
Neurotherapeutics. 2020 Oct;17(4):1511-1524. doi: 10.1007/s13311-020-00875-w.
10
Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.
Neuropsychiatr Dis Treat. 2019 Jul 29;15:2137-2149. doi: 10.2147/NDT.S201029. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验